|By Marketwired .||
|August 5, 2014 02:13 AM EDT||
WINNERSH, UNITED KINGDOM -- (Marketwired) -- 08/05/14 -- Vernalis PLC (LSE: VER) (PINKSHEETS: VNLPY)
Vernalis plc (LSE: VER) today announces its results for the six months ended 30 June 2014.
- Continued strong financial performance ahead of market expectations
- Revenue was £ 6.2 million (H1 2013: £ 7.6 million)
- Frovatriptan royalty income at £ 1.8 million (H1 2013: £ 2.6 million) was in line with market expectations, with one 12.5 kg batch of API delivered to Menarini
- Collaboration income was £ 4.4 million (H1 2013: £ 5.0 million) with £ 1.1 million of milestones earned (H1 2013: £ 2.5 million) and the remaining income derived from FTE funding
- Operating costs (including R&D) before exceptional items marginally higher at £ 9.5 million (2013: £ 9.1 million)
- R&D spend remains largely flat at £ 6.9 million (H1 2013: £ 6.5 million)
- External R&D expenditure increased to £ 1.4 million (H1 2013: £ 1.0 million) due to investment in V158866, V81444 and increased activity on Tris related projects
- Operating loss before exceptional items was £ 3.9 million (H1 2013: £ 2.6 million)
- Loss for the period after exceptional items was £ 4.6 million (H1 2013: profit of £ 4.2 million) including a £ 1.7 million unrealised foreign exchange loss (H1 2013: £ 4.4 million gain) due to the strength of Sterling
- Balance sheet remains strong with £ 70.3 million of cash resources (including cash, cash equivalents and held-to-maturity financial assets) and debt free
- Net decrease in cash resources of £ 6.6 million for the first six months of 2014
- Large proportion of cash still denominated in US dollars, with a £ 1.7 million unrealised foreign exchange loss reported for the period
- Proof-of-Concept (POC) payment on CCP-07 of £ 1.8 million paid to Tris in April 2014
- Underlying cash burn increased to £ 3.8 million (2013: £ 2.6 million) resulting from decline in revenue and small increase in operating costs
Cough Cold Commercial Pipeline:
- NDA for Tuzistra XR (CCP-01) submitted to the FDA at the end of June as expected
- POC achieved for both CCP-07 and CCP-08 triggering milestone payments to Tris in April and July 2014 respectively
- Two further programmes continue in active development at Tris and are targeted to achieve POC before the end of 2014
NCE Development Pipeline:
Frovatriptan (marketed) (Migraine):
- H1 2014 Menarini frovatriptan sales were in line with the same period in 2013 (EUR 13.2 million vs EUR 13.1million)
V81444 (CNS diseases):
- Results of the Phase Ib/II POC study in Attention Deficit Hyperactivity Disorder (ADHD) (April 2014) were promising and the goal is now to partner this programme for further development in ADHD, PD or other CNS disorders where A2A receptor antagonists show potential patient benefit
- The Phase II POC study in spinal cord injury neuropathic pain continues with data now expected in 2015, due to slower than anticipated patient recruitment
- Multiple Phase I and Phase II studies with Novartis continue in a variety of cancers with a focus on non-small-cell lung cancers
Tosedostat - CHR2797 (Cancer):
- The partial clinical hold on investigator led trials was removed by the FDA in January 2014 enabling studies to resume
- CTI Biopharma Corp. (previously Cell Therapeutics Inc.) is hoping that data from these trials in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) may inform the appropriate design of a Phase III study
- CTI Biopharma also announced in June, the initiation of an international co-operation group Phase II study of tosedostat in combination with low dose cytarabine in older patients with AML or MDS
Servier 1 (Cancer):
- Servier signed a global strategic agreement with Novartis to develop and commercialise drug candidates from this collaboration (May 2014)
- The lead molecule from this collaboration with Servier, a selective BCL-2 inhibitor, has progressed into Phase I (June 2014) triggering a £ 0.8 million (EUR 1 million) milestone receipt
- Milestone achieved in collaboration with Asahi Kasei Pharma triggering a £ 0.3 million payment to Vernalis (March 2014)
- Winner of Queen's Award for Enterprise (April 2014)
- Two milestones achieved in our collaborations with Servier triggering, in total, a EUR 0.75 million payment to Vernalis (August 2014)
- Tuzistra XR NDA filing acceptance by FDA (Q3 2014)
- Achieve POC for remaining two cough cold pipeline programmes (before year end 2014)
- V158866 (Pain) - Completion of Phase II POC study (2015)
- AUY922 (Cancer) - Multiple Phase I and II study results (Novartis, timing not disclosed)
- Achieve further milestones under existing research collaborations
- Secure new research collaborations
Ian Garland, Chief Executive Officer, commented, "We have made excellent progress across all aspects of our business during the first half of this year.
The cough cold commercial pipeline has advanced significantly with submission of the Tuzistra XR NDA to the FDA and proof-of-concept achieved for both CCP-07 and CCP-08. We aim to achieve proof-of-concept on the two remaining cough cold products before the end of 2014.
We also announced positive news from the NCE pipeline with promising results from V81444's phase Ib/II study in ADHD. We now aim to partner this programme having significantly enhanced the data package. In the period we also announced that Servier 1, a selective BCL-2 inhibitor had entered Phase 1.
Research continues to perform well and remains self-funding with more milestones earned and five collaborations active during the period. Our financial results overall continue to be strong and we are well positioned for the launch of our first cough cold product into the US market in 2015."
Presentation & Conference Call
Vernalis management will host a presentation at 09.00 am (UK) today (5 August 2014) at Brunswick's offices, 16 Lincoln's Inn Fields, London WC2A 3ED. It will also be available via webcast at http://www.vernalis.com/investor-centre/presentations-and-webcasts and www.cantos.com.
Please contact Valerie Mugridge at Brunswick on +44 (0) 207 396 5325 for details.
-- ends --
Vernalis plc: Ian Garland, Chief Executive Officer +44 (0) 118 938 0015 David Mackney, Chief Financial Officer Canaccord Genuity Limited (Nominated Adviser): +44 (0) 20 7523 8350 Lucy Tilley Dr Julian Feneley Henry Fitzgerald-O'Connor Shore Capital (Joint Broker): +44 (0)20 7408 4090 Bidhi Bhoma Toby Gibbs Brunswick Group: +44 (0) 20 7404 5959 Jon Coles
Notes to Editors
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.
Click on, or paste the following link into your web browser, to view the associated PDF document.
This information is provided by RNS
The company news service from the London Stock Exchange
Feb. 27, 2017 06:45 PM EST Reads: 2,194
Feb. 27, 2017 06:30 PM EST Reads: 2,080
Feb. 27, 2017 06:15 PM EST Reads: 362
Feb. 27, 2017 06:15 PM EST Reads: 8,277
Feb. 27, 2017 05:45 PM EST Reads: 560
Feb. 27, 2017 05:30 PM EST Reads: 535
Feb. 27, 2017 05:30 PM EST Reads: 379
Feb. 27, 2017 05:15 PM EST Reads: 1,688
Feb. 27, 2017 05:15 PM EST Reads: 693
Feb. 27, 2017 05:15 PM EST Reads: 620
Feb. 27, 2017 05:00 PM EST Reads: 369
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
Feb. 27, 2017 04:45 PM EST Reads: 1,786
Feb. 27, 2017 04:45 PM EST Reads: 1,452
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Feb. 27, 2017 03:30 PM EST Reads: 2,297
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Feb. 27, 2017 02:45 PM EST Reads: 2,617